Abstract:Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-associated kinases and transcription factors, and it is essential for oncogenic transformation. Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clinical trials. Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity. Preclinical data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clinical activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer. Many optimized synthetic, small-molecule Hsp90 inhibitors from diverse chemotypes are now in clinical trials. Here, we review the discovery and development of Hsp90 inhibitors and assess their potential. There has been significant learning from studies of the basic biology of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chemical probes. Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (especially multiple myeloma) in which buffering of proteotoxic stress is critical for survival. We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.

Natural Agents Targeting Hsp90 Co-chaperones Could Be Promising Candidates for Viral Resistance Prevention

HSP90: a promising broad-spectrum antiviral drug target

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery

Small Molecule Inhibitors Targeting Heat Shock Protein 90: an Updated Review

Heat Shock Protein 90 Inhibitors: an Update on Achievements, Challenges, and Future Directions.

Design, synthesis and biological evaluation of a new class of Hsp90 inhibitors vibsanin C derivatives

Heat shock protein 90 (Hsp90) Inhibitors: An Update on Achievements, Challenges, and Future Directions.

Discovery and development of natural heat shock protein 90 inhibitors in cancer treatment

Anti-virus reagents targeting the capsid protein assembly

Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function

Heat Shock Protein 90 in Neurodegenerative Diseases

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

Mode of Action of Heat Shock Protein (HSP) Inhibitors against Viruses through Host HSP and Virus Interactions

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

Alternate Strategies of Hsp90 Modulation for the Treatment of Cancer and Other Diseases

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

Natural HSP90 inhibitors as a potential therapeutic intervention in treating cancers: A comprehensive review

Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer

Role of Heat Shock Proteins (HSP70 and HSP90) in Viral Infection